GoldenGolden

Pieris Pharmaceuticals

Pieris Pharmaceuticals is a Boston-based company.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

June 15, 2016
Pieris Pharmaceuticals raises a $16,500,000 corporate funding round from Biotechnology Value Fund.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 26, 2021
BioSpace
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Boston Pharmaceuticals today announced that the companies have entered into an exclusive product license agreement to develop PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein
BioSpace
April 10, 2021
BioSpace
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.